This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following platinum based chemotherapy and anti-PD-1/anti-PD-L1 therapy.
This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 selected advanced/metastatic EC that progressed following platinum based chemotherapy and anti-PD-1/anti-PD-L1 therapy.
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
-
Research Site, Jupiter, Florida, United States, 33458
Research Site, Miami, Florida, United States, 33176
Research Site, Miami Beach, Florida, United States, 33140
Research Site, Orlando, Florida, United States, 32806
Research Site, Honolulu, Hawaii, United States, 96826
Research Site, Peoria, Illinois, United States, 61637
Research Site, Indianapolis, Indiana, United States, 46260
Research Site, Scarborough, Maine, United States, 04074
Research Site, Baltimore, Maryland, United States, 21201
Research Site, Baltimore, Maryland, United States, 21231
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
FEMALE
No
AstraZeneca,
Brian Slomovitz, MD, PRINCIPAL_INVESTIGATOR, Icahn School of Medicine at Mount Sinai
Stephanie Gaillard, MD, PhD, PRINCIPAL_INVESTIGATOR, Johns Hopkins University - Sidney Kimmel Comprehensive Cancer Center (SKCCC)
Christian Marth, MD, PhD, PRINCIPAL_INVESTIGATOR, Medical University of Innsbruck
2028-04-03